印度制药公司Gland Pharma在美国市场增长的驱动下将Q1FY25合并收入增加16%,达到1 401.7卢比。 Indian pharma firm Gland Pharma registers a 16% rise in Q1FY25 consolidated revenue to Rs 1,401.7 crore, driven by US market growth.

印度制药公司Gland Pharma报告说,在美国市场的重大贡献(收入增长27%)的推动下,Gland Pharma公司在Q1FY25的合并收入增加了16%,达到1 401.7卢比。 Indian pharma company Gland Pharma reported a 16% increase in consolidated revenue to Rs 1,401.7 crore for Q1FY25, driven by a significant contribution from the US market, which saw a 27% revenue increase. 基本业务 (Cenexi以外) 收入同比增长14%,达到1,013.4亿卢比,EBITDA同比增长12%,达到294.1亿卢比. Base business (ex-Cenexi) revenue grew 14% YoY to Rs 1,013.4 crore, and EBITDA increased 12% YoE to Rs 294.1 crore. 该公司正在探索收购、许可证发放和共同发展机会,以加速增长。 The company is exploring acquisitions, in-licensing, and co-development opportunities to accelerate growth.